Evidence map›Paper›PMID 39498186›Full record

ArticleIJU case reports2024

Switching cisplatin to carboplatin in chemotherapy for metastatic penile cancer in a patient intolerant to cisplatin.

Keita Sekine, Takahito Suyama, Kazuki Takei, Hiroto Kato, Ken Wakai, Atsushi Okato, Kyokushin Hou, Kazuhiro Araki, Kazuto Yamazaki, Yukio Naya

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJU case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Keita SekineDepartment of Urology Teikyo University Chiba Medical Center Ichihara Chiba Japan.
Takahito SuyamaDepartment of Urology Teikyo University Chiba Medical Center Ichihara Chiba Japan.ORCID https://orcid.org/0000-0002-9487-1397
Kazuki TakeiDepartment of Urology Teikyo University Chiba Medical Center Ichihara Chiba Japan.
Hiroto KatoDepartment of Urology Teikyo University Chiba Medical Center Ichihara Chiba Japan.
Ken WakaiDepartment of Urology Teikyo University Chiba Medical Center Ichihara Chiba Japan.
Atsushi OkatoDepartment of Urology Teikyo University Chiba Medical Center Ichihara Chiba Japan.
Kyokushin HouDepartment of Urology Teikyo University Chiba Medical Center Ichihara Chiba Japan.
Kazuhiro ArakiDepartment of Urology Teikyo University Chiba Medical Center Ichihara Chiba Japan.
Kazuto YamazakiDepartment of Pathology Teikyo University Chiba Medical Center Ichihara Chiba Japan.
Yukio NayaDepartment of Urology Teikyo University Chiba Medical Center Ichihara Chiba Japan.ORCID https://orcid.org/0000-0002-2008-6951

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cisplatin is currently the key drug in the chemotherapy regimen for metastatic penile cancer. There are few reports of alternative medicines for patients who cannot tolerate cisplatin. This report describes a case in which carboplatin was used instead. Case presentation: The patient presented with a chief complaint of edema in the groin area. On close examination, penile cancer (cT2-3N3M0 stage IV) with pelvic lymph node metastasis was diagnosed. He was started on chemotherapy with cisplatin (50 mg/m Conclusion: A case of penile cancer safely and effectively treated with chemotherapy using carboplatin was reported.

Indexed as

advanced penile cancercarboplatinchemotherapycisplatin unfit

Identifiers

PMID39498186
PMCPMC11531887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.